Beneficient

Beneficient announced the closing of a $7.44 million primary capital commitment to Quartus AI Fund II LP, furthering its strategy in AI-focused investments.

Beneficient has amended its Standby Equity Purchase Agreement with Yorkville, reducing the potential equity sale to $100 million and issuing a $2 million convertible promissory note.

Beneficient reported fiscal year 2026 results, highlighting the resolution of GWG Holdings litigation, over $50 million in asset sale proceeds, and a focus on expanding its primary capital solutions and collateral management services.

Beneficient has launched its collateral management services with a new engagement for a Texas state-chartered bank.

Beneficient has amended its previous 8-K filing to confirm the appointment of Mack Hicks to the Executive and Nominating Committees.

Beneficient announced the closing of an $8.75 million primary capital commitment in Quartus AI Fund LP, receiving Series B-10 Preferred Stock convertible into Class A Common Stock.

Beneficient reports significant net losses, ongoing legal battles, and a former CEO's indictment for fraud, raising substantial doubt about its ability to continue as a going concern.

Beneficient reported a significant net loss for Q2 2025, raising substantial doubt about its ability to continue as a going concern, while facing multiple Nasdaq delisting threats and confirmed arbitration awards.

Beneficient's Q3 2025 report reveals a complex financial landscape marked by strategic shifts, legal proceedings, and efforts to maintain Nasdaq compliance.

Beneficient's Q2 2025 report reveals a complex financial picture, marked by a net income of $54.1 million, but also highlighting ongoing concerns about liquidity and substantial debt.

Beneficient reported a net income of $44.3 million for the quarter ended June 30, 2024, primarily driven by investment gains and a release of a loss contingency.

Beneficient's Q3 2024 report reveals a significant net loss, driven by a substantial goodwill impairment, and ongoing operational and financial challenges.

Beneficient reported a significantly reduced net loss for fiscal year 2025, driven by legal settlements and lower operating expenses, though substantial doubt about its ability to continue as a going concern persists.

Beneficient's annual 10-K filing details a year of significant financial restructuring, including a reverse stock split and goodwill impairments, alongside strategic initiatives to address the alternative asset market.

Beneficient Director Peter T. Cangany, Jr. reported the acquisition of 635,690 Class A common shares through a fully vested restricted stock unit award.

Beneficient Director and 10% owner Bruce W. Schnitzer acquired 931,837 shares of Class A common stock through a fully vested RSU grant, increasing his total beneficial ownership to 933,767 shares.

Beneficient's Global Head of Organizations and Distribution, Jeff Welday, reported the acquisition of 30,687 Class A Common Stock shares through a restricted stock unit grant, bringing his total beneficial ownership to 172,394 shares.

Jeff Welday, a Global Head of Organizations and Distribution at Beneficient, reported the acquisition of 1,670 shares of Class A common stock through the settlement of restricted stock units.

Jeff Welday, a Global Head of Organizations and Distribution at Beneficient, sold shares of Class A Common Stock to cover tax withholding obligations related to the vesting of restricted stock units.

Jeff Welday, a key officer at Beneficient, sold Class A Common Stock to cover tax withholding obligations related to the vesting of restricted stock units.

Beneficient's proxy statement details proposals for its 2026 annual meeting, including director elections and incentive plan amendments, amidst extensive litigation, complex related-party dealings, and recent management changes.

Beneficient is seeking stockholder approval for a reverse stock split to increase its share price and maintain its Nasdaq listing, alongside an adjournment proposal.

Beneficient has closed a $1.91 million primary capital transaction by issuing Series B-8 Resettable Convertible Preferred Stock in exchange for a limited partner interest in an investment fund, aiming to expand its alternative asset portfolio and liquidity solutions.

Beneficient has once again adjourned its Annual Meeting of Stockholders to May 29, 2025, due to an insufficient number of shares present to constitute a quorum.

Beneficient's proxy statement outlines its mission to democratize alternative asset investment for underserved investors through tools like AltQuote and AltAccess.

Beneficient (BENF) has adjourned its Annual Meeting of Stockholders for a second time to May 28, 2025, due to an insufficient number of shares present to constitute a quorum.

Beneficient has filed an S-1 registration statement to allow for the resale of up to 55,671,296 shares of its Class A common stock by various selling stockholders.

Beneficient has filed an S-1 registration statement for the resale of up to 71,017,840 Class A common stock shares by selling holders, while grappling with significant net losses, going concern doubts, and ongoing legal and regulatory issues.

Beneficient files an amendment to its registration statement to register the potential resale of over 203 million shares of Class A common stock by selling holders.

Beneficient amends its registration statement to offer up to 203 million shares of Class A common stock through various agreements, including a standby equity purchase agreement with Yorkville.

Beneficient is registering for resale over 203 million shares of its Class A common stock by selling holders, including shares potentially issued under a standby equity purchase agreement with Yorkville.

James G. Silk, CEO of Beneficient, has converted approximately $4.58 million of Preferred A-1 Unit Accounts into 1,101,082 Class A shares, as detailed in a Schedule 13D filing.

Mack Hicks replaces Thomas O. Hicks as a reporting person in an amended Schedule 13D filing for Beneficient.

Hatteras Investment Partners, LP filed an amendment to Schedule 13G, reporting 0% beneficial ownership of Beneficient Class A common stock as of September 30, 2025.

Hatteras Investment Partners, LP has filed an Amendment No. 5 to its Schedule 13G, reporting a 6.7% beneficial ownership stake in Beneficient Class A common stock.

Hatteras Investment Partners, LP has filed an amended Schedule 13G, reaffirming its 6.7% beneficial ownership stake in Beneficient Class A common stock as of March 31, 2025.

Hatteras Investment Partners, LP has filed a Schedule 13G, reporting beneficial ownership of 6.9% of Beneficient's Class A common stock as of December 31, 2024.